IL17A-IN-1 (Compound 72) is an orally active inhibitor of Interleukin 17A. This compound is applicable in research related to inflammatory and autoimmune diseases, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and cancer.

IL17A-IN-1 inhibits Hela cell proliferation with an IC50 of 0.005 µM.

IL17A-IN-1, administered orally at a dosage of 10 mg/kg as a single dose, can suppress the secretion of CXCL1 in the plasma of C57BL/6 mice (hIL17A-induced mouse CXCL1 PD model) by 53%. (Recombinant human IL17A injected subcutaneously in mice induces plasma CXCL1 secretion.) In a separate study, male Sprague-Dawley rats weighing 360-460 g were given IL17A-IN-1 via intravenous injection at 0.3 mg/kg, resulting in pharmacokinetic parameters of 1.19, with the following specifics: V ss (L/kg) at 5.0, a half-life (t 1/2) of 3.6 hours, and clearance rates (CLp/CLp,u) of 1.1/6.1 L/h/kg.